Erasca Inc ERAS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
-
Erasca to Present at Upcoming Investor Conferences in September
-
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 129
- Website
- https://www.erasca.com
Comparables
Valuation
|
Metric
|
ERAS
|
PRLD
|
CGON
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.62 | 0.64 | 4.57 |
Price/Sales | — | — | 252.33 |
Price/Cash Flow | — | — | — |
Price/Earnings
ERAS
PRLD
CGON
Financial Strength
|
Metric
|
ERAS
|
PRLD
|
CGON
|
|---|---|---|---|
Quick Ratio | 16.41 | 7.71 | 46.66 |
Current Ratio | 16.79 | 7.83 | 47.57 |
Interest Coverage | — | — | — |
Quick Ratio
ERAS
PRLD
CGON
Profitability
|
Metric
|
ERAS
|
PRLD
|
CGON
|
|---|---|---|---|
Return on Assets (Normalized) | −25.42% | −40.98% | −15.24% |
Return on Equity (Normalized) | −31.11% | −46.70% | −26.61% |
Return on Invested Capital (Normalized) | −31.15% | −44.57% | −25.60% |
Return on Assets
ERAS
PRLD
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ptrqccdybf | Vjmp | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Htwdvvq | Sqthpn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nndykqty | Gvjmyj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xfhqhvj | Vbbsnkg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Cbrnrpcb | Czck | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ygtjxkph | Cdyfs | $28.1 Bil | |||
| Moderna Inc
MRNA
| Yjyjchr | Kjb | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Rvzmlkvy | Dsnn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qtfmgnmk | Mbtbvf | $13.4 Bil | |||
| Incyte Corp
INCY
| Jrwnmhsh | Zsggncr | $12.7 Bil |
United States